Acute myeloid leukemia bearing t(7;11)(p15;p15) is a distinct cytogenetic entity with poor outcome and a distinct mutation profile: comparative analysis of 493 adult patients Acute myeloid leukemia (AML) with t(7;11)(p15;p15), which results in a NUP98-HOXA9 fusion, is a distinct entity, but this subtype has not been characterized in detail. In a comprehensive study comparing 11 such patients with another 482 adult patients, we found that those with t(7;11) were younger (P ¼ 0.0076) and female (P ¼ 0.0111), with almost all having the M2-subtype of AML (Po0.0001). Even when those with low-risk karyotypes were excluded, patients with t(7;11) had poorer overall survival than the other AML group (median 13.5 and 20 months, respectively, P ¼ 0.045) and poorer relapse-free survival (median 6 and 12 months, respectively, P ¼ 0.003). The NUP98-HOXA9 fusion was strongly associated with KRAS and WT1 mutations (P ¼ 0.015 and P ¼ 0.0018, respectively). We characterized four varieties of this fusion, among which NUP98 exon 12/HOXA9 exon 1b was present in all 11 patients. We developed a highly sensitive and specific assay to quantify the abundance of leukemic cells, and found that the fusion remained detectable in morphological complete remission, even after allogeneic stem cell transplantation, suggesting that this disease was highly refractory to very intensive treatment. AML with NUP98-HOXA9 fusion therefore appears to have a distinct clinical and biological profile, and should be regarded as a poor prognostic group.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of diseases in terms of clinical presentation, genetic alterations and response to treatment. Accumulating evidence has identified numerous parameters that are able to stratify this complex disease. Traditionally, the karyotype of leukemic cells is one of the most important prognostic factors. A recent focus on the genetic alterations in AML has further contributed to our ability to distinguish subgroups of this heterogeneous entity.
Acute myeloid leukemia with chromosomal translocation t(7;11)(p15;p15) was first reported more than 20 years ago. [1] [2] [3] Subsequent studies indicated that this subtype of AML was a specific entity occurring preferentially in Asian countries, and usually presented with dyspoietic cell morphology and considerable numbers of mature myeloid cells in the bone marrow. [4] [5] [6] [7] [8] Not only was this translocation seen in de novo AML but also, although rarely, in chronic myeloid leukemia and myelodysplastic syndrome. [9] [10] [11] [12] [13] [14] [15] The translocation was found to result in a fusion between NUP98 and HOXA9. 16, 17 Subsequent studies showed that several other HOX genes could be fused with NUP98 in myeloid leukemia. [18] [19] [20] [21] [22] A number of animal studies have described the pathogenetic role of NUP98-HOXA9 in leukemogenesis. [23] [24] [25] [26] [27] Reports concerning this translocation have been limited by the fact that they generally included only a small number of patients, did not compare this group of patients directly with other AML patients, and offered limited clinical description. In the current analysis of 493 adult AML patients, we found 11 patients bearing t(7;11)(p15;p15). To better characterize this subgroup of patients, we performed a comprehensive comparison of clinical and biological characteristics between these and the remaining AML patients. We determined that AML with t(7;11)(p15;p15) was a distinct cytogenetic and clinical entity that was closely associated with FAB M2-subtype, female sex, younger age, mutations of WT1 and KRAS, and poor outcome. We also devised a highly sensitive and specific real-time PCR assay to quantify and trace this subset of leukemic cells, and found that this disease was highly refractory to intensive treatment, including allogeneic stem cell transplantation, as shown by the high copy number of NUP98-HOXA9 fusion transcripts in most samples obtained in complete remission. To the best of our knowledge, this is the most comprehensive study to date on de novo adult AML patients with t(7;11).
Materials and methods

Patients
Between 1994 and 2007, we recruited 493 consecutive adult patients newly diagnosed with de novo AML. The diagnosis was based on a complete examination of hematology, serum biochemistry, bone marrow cell morphology, cytochemical staining, immunophenotyping and chromosomal analysis. All patients signed informed consent before their leukemic cells were collected for diagnostic and molecular studies.
Immunophenotyping
To characterize the phenotype of the leukemic cells, we used a panel of monoclonal antibodies to the following: myeloidassociated antigens, including CD13, CD33, CD11b, CD15, CD14 and CD41a; lymphoid-associated antigens, including CD2, CD5, CD7, CD19, CD10 and CD20; and the lineage nonspecific antigens HLA-DR, CD34 and CD56. Expression of surface antigens on leukemic cells was detected by an indirect immunoalkaline phosphatase method 28 before 1998, and by flow cytometry thereafter. 29 
Cytogenetic analysis
Bone marrow samples were aspirated into heparinized syringes, and chromosomal analyses by the G-banding method were performed after 1-3 days of unstimulated culture as described earlier. 28 
Analysis of genetic mutations
Bone marrow mononuclear cells were isolated using FicollHypaque gradient centrifugation. The isolated cells were frozen and stored at À80 1C for further genetic analysis. We analyzed mutations in several genes, including NPM1, FLT3/ITD, FLT3/TKD, AML1, KRAS, NRAS, CEBPA, MLL/PTD, JAK2, PTPN11 and WT1. The detailed experimental protocol, with primer sequences, has been described earlier.
29-33
Analysis of NUP98-HOXA9 break points , using the same protocol as the earlier amplification. The products were resolved on 2% agarose gels, after which the products were purified and sent out for direct sequencing.
Real-time PCR for NUP98-HOXA9
The sequences of the forward and reverse primers and probe, respectively, were as follows: 5 0 -GATTTAATACTACGACAGCC ACTTTGG-3 0 ; 5 0 -GCTGGGTTGTTTTTCTCTATCAACT-3 0 ; and 5 0 -TTTGGAGCCCCCCAGGCCC-3 0 . The probe was labeled with FAM and TAMRA (Applied Biosystems, Foster City, CA, USA). In each tube, 20 ml of reaction mixture contained 500 nM each primer, 250 nM probe, 10 ml master mix (FastStart TaqMan Probe Master, Roche Diagnostics, Mannheim, Germany) containing 4.5 mM magnesium ion, and 4 ml of cDNA. The PCR program was carried out at 95 1C for 10 min followed by 45 cycles of 95 1C for 10 s and 60 1C for 1 min on an iQ5 machine (BioRad, Hercules, CA, USA). Each sample was tested independently at least twice. The human phosphoprotein (HUPO) gene (Applied Biosystems) was used as a loading control. 34 The plasmid used to generate the standard curve was made by TA cloning of the nested PCR product (Yeastern Biotech, Taipei, Taiwan).
Statistics
The w 2 test was used to calculate the significance of association between t(7;11) and other discrete parameters, such as expression of antigens, cytogenetics or mutation of a specific gene. The Mann-Whitney test was used to compare continuous variables. The Kaplan-Meier curve was calculated using SPSS software (Chicago, IL, USA).
Results
Clinical and genetic characteristics of patients with t(7;11)(p15;p15)
Among 493 AML patients, 11 patients (2. 23%) were found to have t(7;11)(p15;p15). The detailed laboratory data and clinical outcome of these patients are listed in Table 1 . The marrow of patients in this group contained a mixture of blasts and more mature myeloid cells. Most of the patients presented with dyspoietic features and Auer rods in the leukemic cells. All but one patient had the FAB M2-subtype. Compared with the other AML patients, those bearing this translocation were younger (P ¼ 0.0076) and predominantly female (P ¼ 0.0111), and tended to have a higher lactate dehydrogenase level (P ¼ 0.0553) ( Table 2 ). The immunophenotyping profile of patients in this group was not different from that of the others (data not shown). Four of the 11 patients with t(7;11) had concurrent WT1 mutations. Some patients with t(7;11) also had FLT3/ITD, and mutations in NRAS and KRAS, each of which is a class I mutation that confers a proliferation or survival advantage to hematopoietic cells. In contrast, none of the 11 patients had MLL/PTD or mutations in AML1, NPM1 or CEBPA, which belong to class II gene mutations that affect transcription factors and lead to impaired hematopoietic differentiation (Table 1) . 35, 36 We note that we could not exclude the possibility that mutations of other class II genes which we did not analyze in this study were present in these patients. Further analysis showed that t(7;11)(p15;p15) was positively associated with mutations in WT1 and KRAS (Table 2 ). For patients who were younger than 65 years and had received anthracycline and cytarabinecontaining intensive chemotherapy (n ¼ 326), those carrying t(7;11) (n ¼ 10) had worse overall survival (median 13.5 vs 38 months, P ¼ 0.009), relapse-free survival (median 6 vs 15 months, Po0.0001) (Figures 1a and b respectively) and disease-free survival (median 5 vs 11.7 months, P ¼ 0.003, data not shown). However, most patients with t(7;11)(p15;p15) had achieved a complete remission after intensive chemotherapy (Table 1) . Even when we excluded 82 patients with good-risk karyotypes (inv(16), t(15;17) and t(8;21)), patients with t(7;11) still had with poorer overall survival (median 13.5 vs 20 months, P ¼ 0.045), relapse-free survival (6 vs 12 months, P ¼ 0.003) (Figures 1c and d respectively) and disease-free survival (5 vs 9 months, P ¼ 0.027, data not shown) compared with other patients. Multivariate analysis indicated that this translocation was an independent factor predicting shorter overall survival, relapse-free survival and disease-free survival (P ¼ 0.015, 0.001 and 0.003, respectively). The survival differences were equally significant when we restricted our analysis to patients with the M2-subtype of AML (6 vs 15 months, P ¼ 0.001 for relapse-free survival; 13 vs 38 months, P ¼ 0.040 for overall survival; and 6 vs 12 months, P ¼ 0.007 for disease-free survival).
Four types of fusion break points in NUP98-HOXA9
Earlier reports have described three types of fusion sequence, which appeared to result from alternative splicing of NUP98 and HOXA9. 7, 12, 16, 17 In this study, we found four types of fusion, each of which was in-frame ( Figure 2 ). Leukemic cells from all patients with t(7;11) contained at least two fusion products of different intensity (Figure 2) . Sequencing showed the longest transcript and major product in all patients to be a fusion between NUP98 exon 12 and HOXA9 exon 1b, with the other representing a fusion between NUP98 exon 11/12 and HOXA9 exon 1b/2 ( Figure 2 ).
Use of real-time PCR to quantify and trace the leukemic cells
To quantify and trace leukemic cells in patients during their clinical course, we designed a pair of primers and a probe for real-time PCR. The amplified region, which covered the junction between exon 12 of NUP98 and exon 1b of HOXA9, was clearly present in each of the 11 patients (Figure 2) . We tested the efficiency of amplification by serially diluting test plasmids into a complex cDNA background derived from NB4 cells lacking the target fusion gene, and found the method to be highly sensitive, with the ability to detect as few as 10 copies with nearly 100% amplification efficiency (Figure 3a) . No signals were seen when cDNA of NB4 cells alone was amplified (Figure 3a) . We also serially diluted one patient's cDNA (patient no. 9) into a complex cDNA background from NB4 cells, and found a similarly robust and specific amplification (Figure 3b) . We then quantified the abundance of leukemic cells from four patients who had serial follow-up samples taken along their treatment course (Figure 4) . Interestingly, we found that neither intensive chemotherapy nor stem cell transplantation had appreciably reduced the tumor burden of any of the four patients ( Figure 4) . Of the 30 samples tested, only 2 samples yielded no detectable signal (Figure 4b , patient no. 11 and Figure 4b , patient no. 6). Most samples contained fewer than 5% blasts in the bone marrow, but had evident residual disease as shown by real-time PCR ( Figure 5 ).
Discussion
Although myeloid leukemia with t(7;11)(p15;p15) was first reported more than 20 years ago, comprehensive clinical and biological analyses necessary for its detailed characterization are still lacking. To the best of our knowledge, this study includes the largest number of patients with t(7;11) to date. We carried out a comprehensive analysis of the clinicopathological characteristics, genetic alterations and fusion break points at presentation in patients with t(7;11), and developed a highly sensitive and specific real-time PCR assay to quantify the number of residual leukemic cells. We also compared AML patients with and without this translocation.
Significantly more female than male patients were found to bear t(7;11) (Table 2) , a finding which differs with the results of an earlier study. 3 However, grouping the patients in this study with all of those reported earlier confirms that female patients with t(7;11) are more numerous than males (18 vs 13). 3, [7] [8] [9] [10] [11] [12] 14, 15 We cannot exclude the possibility that the discrepancy with one earlier reported was related to different definitions of the molecular entities in question, or to a difference in the ethnic origins of the respective patient populations. Other prominent features in this group of patients were younger age, more frequent FAB M2-subtype and poor outcome. In an important study of NUP98 rearrangements in hematopoietic malignancies, 37 the demographic analysis of patients with t(7;11) did not show a tendency toward female sex or young age. However, in that study the molecular level of the rearrangement was incompletely defined, in contrast to our study where only the NUP98-HOXA9 fusion was investigated. Thus, molecular heterogeneity, disease rarity and ethnic differences might contribute to the observed discrepancies in the reported epidemiology of AML with t(7;11).
Although most patients achieved a morphological complete remission after chemotherapy, all but one relapsed (Table 1) . This high relapse rate indicated that a considerable number of morphologically undetectable leukemic cells remained after Table 1 Clinical, pathological and genetic features of AML patients with t(7;11)(p15;p15) AML with NUP98-HOXA9 W-C Chou et al chemotherapy, consistent with the results of our real-time PCR assay, which clearly showed the persistence of abundant disease cells following intensive chemotherapy even when fewer than 5% of blast cells in the patients' bone marrow remained. This indicated that many leukemic cells bearing NUP98-HOXA9 fusion presented with a misleadingly mature morphology. Thus, morphological assessment of marrow blast percentage alone is insufficient to allow an accurate assessment of disease status after chemotherapy. As NUP98-HOXA9 plays a critical role in leukemogenesis in this group of patients, it is most likely that this fusion persists as long as the leukemic cells survive. Our realtime PCR assay detected signals in all but two samples obtained from patients in complete remission, suggesting that this mutation confers a refractory character on the disease, and may be a useful marker for quantifying minimal residual disease. NUP98-HOXA9 has been found to cooperate with BCR-ABL to accelerate leukemogenesis in animals. 24 Several studies using microarrays, 26, 27 identification of retroviral integration sites 38 or co-transfection 23 have identified genes that potentially cooperate with the NUP98-HOXA9 fusion during leukemia development in both animals and humans. It has been proposed that NUP98-HOXA9 might induce a preleukemic state, requiring the activation of other oncogenes, such as MEIS1 and other HOX family genes, to complete formation of the leukemia. In this study, we used a novel method to identify genes that potentially cooperate with NUP98-HOXA9 in human leukemia. Our genetic mutation analysis on human leukemic cells indicated that the KRAS and WT1 mutations were significantly associated with this fusion gene, implying a critical role of these two genetic alterations in cooperation with NUP98-HOXA9 in the pathogenesis of this subtype of leukemia. Both KRAS and WT1 are known to be important factors in leukemic pathogenesis. Mutation of WT1, which normally induces cellular quiescence and differentiation, 39 occurs in 10% of AML patients with a normal karyotype, and may be associated with drug resistance. 40 KRAS mutations occur in about 5% of AML patients. 41 Although the prognosis of AML patients bearing KRAS mutations appears not to differ from that of others, 41 these mutations result in constitutive activation of the protein, which would be expected to promote tumor cell proliferation. The strong association between NUP98-HOXA9 and WT1 and KRAS mutations suggests that the latter two gene alterations could interact with NUP98-HOXA9 in acceleration of leukemogenesis and in conferring a poor response to chemotherapy. Although WT1 upregulation was seen in primary human CD34 þ hematopoietic cells transduced by NUP98-HOXA9, the mechanism for a potentially close association between the WT1 mutation and this fusion remain to be investigated. No earlier reports have shown a correlation between this fusion gene and KRAS mutations. The genetic events underlying AML pathogenesis appear to be classified into two broadly defined complementation groups: class I, which includes FLT3 and RAS mutations; and class II, including the CEBPA and AML1 mutations. 35, 36 HOX genes are targets of polycomb genes that are important in cell differentiation, [42] [43] [44] suggesting that NUP98-HOXA9 might belong to the class II group. Our finding that NUP98-HOXA9 frequently occurred simultaneously with class I mutations such as KRAS and FLT3/ITD, but not with the class II mutations, such as AML1 and CEBPA that we analyzed (Table 1) , supports the hypothesis of multistep AML pathogenesis that may require the cooperation of mutations in both classes. 35 The role of WT1 mutation in leukemogenesis is still not completely defined. It may belong to another class of gene alteration. From this comprehensive study, containing the largest number of AML patients bearing t(7;11)(p15;p15) to date, we conclude that this subtype of AML is a special entity with a number of distinct clinical and biological characteristics. Patients with this translocation should be suspected to have poor prognosis, which warrants the development of novel therapies directed specifically toward this population. In addition, their disease status should be monitored by mutationspecific real-time PCR, as assessment based on morphological observation appears to have the potential to be extremely misleading. 
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